MARKET

PRAX

PRAX

Praxis Precision Medicines, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.68
-0.13
-0.82%
After Hours: 15.68 0 0.00% 16:00 07/29 EDT
OPEN
15.97
PREV CLOSE
15.81
HIGH
16.18
LOW
15.46
VOLUME
195.01K
TURNOVER
--
52 WEEK HIGH
60.95
52 WEEK LOW
15.37
MARKET CAP
576.23M
P/E (TTM)
-6.7832
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26)
Benzinga · 2d ago
Praxis Precision Medicines Posts Trial Titled 'A Clinical Trial of Adjunctive PRAX-114 in Participants With Major Depressive Disorder' To ClinicalTrials.Gov
https://clinicaltrials.gov/ct2/show/NCT04969510
Benzinga · 07/20 14:56
How Many Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Do Institutions Own?
Every investor in Praxis Precision Medicines, Inc. ( NASDAQ:PRAX ) should be aware of the most powerful shareholder...
Simply Wall St. · 07/19 12:27
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15)
Benzinga · 07/16 11:37
Praxis Precision Medicines to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders charac...
GlobeNewswire · 07/06 13:00
Aeglea BioTherapeutics Appoints Marcio Souza to Board of Directors
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of to its boa...
PR Newswire - PRF · 06/22 12:30
Stocks That Hit 52-Week Lows On Thursday
    On Thursday morning, 9 companies achieved new lows for the year.
Benzinga · 05/27 14:26
Praxis Precision Medicines names Tim Kelly as chief financial officer
Praxis Precision Medicines (PRAX) announces the appointment of Tim Kelly as the company's chief financial officer, effective immediately.Kelly joins Praxis from Foundation Medicine, where he served as chief financial officer and
Seekingalpha · 05/25 13:04
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRAX. Analyze the recent business situations of Praxis Precision Medicines, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRAX stock price target is 63.33 with a high estimate of 70.00 and a low estimate of 55.00.
EPS
Institutional Holdings
Institutions: 68
Institutional Holdings: 36.62M
% Owned: 99.65%
Shares Outstanding: 36.75M
TypeInstitutionsShares
Increased
25
1.94M
New
11
91.58K
Decreased
16
360.70K
Sold Out
12
1.25M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Non-Executive Chairman/Independent Director
Dean Mitchell
President/Chief Executive Officer/Director
Marcio Souza
Chief Financial Officer/Treasurer
Timothy Kelly
General Counsel/Secretary
Alex Nemiroff
Other
Bernard Ravina
Other
Nicole Sweeny
Independent Director
Jeffrey Chodakewitz
Independent Director
Merit Cudkowicz
Independent Director
Gregory Norden
Independent Director
Stefan Vitorovic
Independent Director
William Young
No Data
  • All
  • Financials
  • Insiders
More
About PRAX
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance. Its development stage products include PRAX-114, PRAX-944 and PRAX-562. PRAX-114 is an extrasynaptic-preferring gamma-aminobutyric acid-A (GABAA) receptor positive allosteric modulator (PAM) for the treatment of patients suffering from major depressive disorder (MDD) and perimenopausal depression (PMD). PRAX-944 is a differentiated selective small molecule inhibitor of T-type calcium channel, for the treatment of essential tremor (ET). PRAX-562 is the selective, persistent sodium current blocker in development for the treatment of a range of CNS disorders.

Webull offers kinds of Praxis Precision Medicines Inc stock information, including NASDAQ:PRAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRAX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRAX stock methods without spending real money on the virtual paper trading platform.